

Development Considerations of Antifungal Drugs to Address Unmet Medical Need —August 4, 2020

Speakers and Panelists: Affiliations and Disclosures

David Angulo, MD

Chief Medical Officer
Scynexis, Inc.
Jersey City, NJ

John Bennett, MD

Senior Investigator
Clinical Mycology Section
NIAID, NIH
Bethesda, MD

Radu Botgros, MD

Scientific Officer
Office of Biological Health Threats and Vaccines Strategy
European Medicines Agency (EMA)
Amsterdam, the Netherlands

Helen Boucher, MD

Chief, Division of Geographic Medicine and Infectious Diseases
Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR)
Director, Heart Transplant and Ventricular Assist Device Infectious Diseases Program
Professor of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, MA

Tom M. Chiller, MD

Chief, Mycotic Diseases Branch
Associate Director of Global Programs
Division of Foodborne, Waterborne, and Environmental Diseases
Nation Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Philip Colangelo, Pharm.D., PhD

Clinical Pharmacology Team Leader,
Division of Clinical Pharmacology IV
OTS, CDER, FDA
Silver Spring, MD

Aaron Dane, MSc

Director
DaneStat Consulting Limited
Macclesfield, United Kingdom

David Denning

Professor of Infectious Diseases in Global Health
The University of Manchester
Manchester, UK

Cheryl Dixon, PhD

Statistical Reviewer
Division of Biometrics IV (DBIV), Office of Translational Sciences (OTS)
CDER, FDA
Silver Spring, MD

Dennis Dixon, PhD

Chief, Bacteriology and Mycology Branch
National Institute of Allergy and Infectious Diseases (NIAID), NIH
Bethesda, MD

John Farley, MD, MPH

Director
Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

Karen Higgins, Sc.D.

Statistical Team Leader
DBIV, OTS
OND, CDER, FDA
Silver Spring, MD

Michael R. Hodges, MD, BSc.

Chief Medical Officer
Amplify Pharmaceuticals, Inc.,
San Diego, CA

William Hope, Ph.D.

Dame Sally Davies Chair of AMR Research
Director, Centre of Excellence in Infectious Diseases Research
Department of Molecular and Clinical Pharmacology
University of Liverpool
United Kingdom

Caroline Jjingo, MD, MPH

Clinical Reviewer

Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)

OND, CDER, FDA

Silver Spring, MD

Aspasia Katragkou, MD, PhD

ESPID Fellow, Transplantation-Oncology Infectious Disease Program

Weill Cornell Medicine

New York, New York

Laura Kovanda, Ph.D.

Senior Director, Global Development Project Leader

Astellas Pharma Global Development, Inc.

Northbrook, IL

Baoying Liu, MD, PhD

Program Officer

NIAID, NIH

Rockville, MD

Shawn Lockhart, Ph.D.

Senior Clinical Laboratory Advisor

Senior Advisor for AMR

Mycotic Diseases Branch

Centers for Disease Control and Prevention

Atlanta, GA

Johan Maertens, MD

Associate Professor of Hematology

University Hospital

Leuven

Belgium

Kieren Marr, MD, MBA

Professor of Medicine

Vice Chair of Medicine for Innovation in Healthcare Implementation

Director of Transplant and Oncology Infectious Diseases

Johns Hopkins University School of Medicine

Baltimore, MD

Jason Moore, Pharm.D.

Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP)
Office of Clinical Pharmacology (OCP)
FDA/CDER/OTS
Silver Spring, MD

Sumathi Nambiar, MD, MPH

Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Elizabeth O'Shaughnessy, MD

Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Luis Ostrosky-Zeichner, MD

Vice-Chair of Medicine
Director of the Laboratory of Mycology Research
McGovern Medical School
Houston, TX

Peter Pappas, MD

Professor of Medicine
Medicine/Infectious Diseases Department
University of Alabama
Birmingham, AL

Thomas Patterson, MD

Vice-Chair for Faculty Development
Chief, Division of Infectious Diseases
Professor of Medicine
Director, San Antonio Center for Medical Mycology
The University of Texas Health Science Center at San Antonio
San Antonio TX

John Perfect, MD

Professor of Medicine
James B. Duke Distinguished Professor of Medicine
Chief, Division of Infectious Diseases
Professor in Molecular Genetics and Microbiology
Durham, NC

John Rex, MD

Chief Medical Officer & Director
F2G, Ltd
Manchester, UK

Taylor Sandison, MD, MPH

Chief Medical Officer
Cidara Therapeutics
San Diego, CA

Matthew Schueler

Founder
Henry Schueler Foundation
Chicago, IL

George Thompson, MD

Associate Professor of Medicine
Department of Medicine, Division of Infectious Diseases
Department of Medical Microbiology and Immunology
UC-Davis Medical Center

Thomas Walsh, MD, PhD

Founding Director, Transplantation-Oncology Infectious Diseases Program
Chief, Infectious Diseases Translational Research Laboratory
Professor of Medicine, Pediatrics, and Microbiology & Immunology
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital
Henry Schueler Foundation Scholar
Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation
New York, NY

Yuliya Yasinskaya, MD

Clinical Team Leader
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Erin Zeituni, PhD

Preclinical Services Program Manager
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Lanling Zou, MD, PhD

Bacteriology Program Officer
Chief, Translational Sciences Section
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Disclosures

David Angulo is an employee of SCYNEXIS, Inc.

Helen Boucher is the editor of ID Clinics of North America, Antimicrobial Agents and Chemotherapy, and the Sanford Guide; Treasurer of the Infectious Diseases Society of America, and Voting Member of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCRB), and retiree from the ID Board of the American Board of Internal Medicine.

Aaron Dane of DaneStat Consulting is a statistical consultant for the Pharmaceutical and Biotechnology Industry. He has acted as a consultant for Achaogen, Allegra, Amicrobe, Amplyx, Artizan, Cidara, ContraFect, Davolterra, Destiny, F2G, Geom, GSK, Gyroscope, Kymab, Mironid, Modis, Nabriva, Orca, Pfizer, Phico, Pled, Roche, Scynexis, Spero, TenNor, Transcrip, VenatoRx and Zavante.

David Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.

William Hope is (or has been) a consultant to F2G, Amplyx, Pfizer and Gilead.

Laura Kovanda is a full-time employee of Pharma Company Astellas Pharma Global Development, Inc.

Kieren Marr is founder and CEO of MycoMed Technologies. Consultant and Advisory Board member for Cidara Therapeutics and Sfunga Therapeutics. She has consulted for Amplyx Pharmaceuticals, Astellas Pharma, Advaxis, Chimerix, F2G Ltd, Genentech, Incyte Corp, Merck & Co., OncoSec, RTI Surgical, Scynexis, Inc. and Vical. She receives authorship and editorial royalties from UpToDate and a grant from Merck.

John Rex is Chief Medical Officer & Director, F2G, Ltd.; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; Novo Holdings; and Roche Pharma Research & Early Development; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allecra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; Novo Holdings; Innocoll; Vedanta; Progenity; Nosopharm SA; Roivant Sciences; and Shionogi Inc.

Luis Ostrosky-Zeichner has received research funding and/or personal honoraria for consulting or speaking from Pfizer, Merck, Astellas, Cidara, Scynexis, F2G, Amplyx, Gilead, Therapeutics, Inc, Viracor, Octapharma, Biotoscana, Stendhal, Mayne, Takeda, RealTime labs, and Viracor.

Thomas Patterson has received research grants to UT Health San Antonio from Cidara and F2G and has served as a consultant for Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, & Toyama

Taylor Sandison is a full-time employee of Cidara Therapeutics.

George R. Thompson, has consulted for: Amplyx, Astellas, Cidara, F2G, Mayne, Vical. DSMB for Pfizer. Research support from: Amplyx, Astellas, Cidara, F2G, Gilead, Mayne, Merck, Regeneron, Vir.

Thomas Walsh has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, and Tetrphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.